search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
NEWS


JAKA Biotech gives global debut to neuro-soothing ingredient


JAKA Biotech gave a global debut to Gavient PY, its neuro-soothing skin care active ingredient, at the PCHi 2026 trade show in Hangzhou, China. Gavient PY targets the excessive


activation of TRPV1/TRPV4 channels in keratinocytes, thus reducing glutamate overproduction at the source. Meanwhile, it inhibits glutamate


receptor activation in neuron-like cells to block abnormal signal transmission of nerve impulses. During the development process,


innovative biological models of cell-to-cell communication and ‘glutamatergic neurotransmission


Syensqo brews coffee-based scalp care active


Syensqo launched Re2 Coffea Arabica Peptide, a novel, clinically proven scalp care active derived from coffee grounds, at in-cosmetics Global 2026 in Paris, France. The ingredient leverages


proprietary molecular docking technology to selectively extract targeted peptide fragments that helps soothe the scalp, boost hydration, reinforce barrier function and reduce hair loss by over 80%. In addition to Re2 Coffea


Arabica Peptide, Syensqo introduced new science-based solutions that unlock fresh opportunities for formulators in skin and hair care. Cerafy Clear NP Boost is an


innovative ceramide-loaded liposome delivery system, uniquely designed to enhance ceramide release into the skin. Dermalcare Velvet is a plant-


based polymeric emollient and natural alternative to lanolin, suitable for baby care, skin care, makeup and sun care. Polycare Split Therapy SGI


is a biobased polymer sourced from Syensqo’s Sustainable Guar Initiative (SGI) that seals up to 90% of split ends after a single use.


www.personalcaremagazine.com May 2026 PERSONAL CARE MAGAZINE


functionality’ were constructed for the first time. In vitro tests show that Gavient PY


can significantly inhibit the abnormal activation of TRPV4, TRPV1, PAR2, and HRH1 receptors at extremely low doses. In neuron-like cell model, Gavient


PY can effectively suppress the activation of glutamate receptor activation, simultaneously down- regulate glutamate release, and block abnormal signal transmission of nerve impulses.


enhance the skin’s tolerance to external irritants. Shanghai-based JAKA Biotech


In clinical tests, both lactic acid stinging and capsaicin stimulation models show that Gavient PY at a dosage of 0.1% can rapidly relieve skin discomforts caused by external stimuli within five minutes. Long-term use can significantly


also showcased Lumiroot GD, its newly launched whitening ingredient. Its core component is glabridin, a classic and widely recognized whitening ingredient. Clinical tests have shown that


Lumiroot GD can rapidly reduce the skin’s melanin index (MI value) and increase the skin’s ITA° value within seven days, significantly improving skin brightness within 14 days.


13


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100